Aug 11 (Reuters) - Mersana Therapeutics Inc
* Mersana announces second quarter 2017 financial results and provides business updates
* Q2 loss per share $6.33
* Q2 earnings per share view $-0.69 — Thomson Reuters I/B/E/S
* Mersana therapeutics - expects cash, cash equivalents and marketable securities will enable it to fund its operating plan through at least mid-2019.
* Mersana therapeutics - cash, cash equivalents and marketable securities as of june 30, were $77.2 million, compared with $100.3 million as of december 31, 2016
* Mersana therapeutics inc - qtrly collaboration revenue $3.7 million versus $6.2 million
* Q2 earnings per share view $-0.69, revenue view $3.9 million — Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: